¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"energy replacement time"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • real time PCR
    ½Ç½Ã°£ÁßÇÕÈ¿¼Ò¿¬¼â¹ÝÀÀ
  • real time study
    ½Ç½Ã°£°Ë»ç
  • real time ultrasonography
    ½Ç½Ã°£ÃÊÀ½ÆÄÃÔ¿µ(¼ú)
  • recirculation time
    Àç¼øÈ¯½Ã°£
  • recovery time
    ȸº¹½Ã°£
  • retention time
    Á¤Ã¼½Ã°£
  • rise time
    »ó½Â½Ã°£
  • spin lattice relaxation time
    ½ºÇɰÝÀÚÀ̿Ͻð£
  • spin-spin relaxation time
    ½ºÇɽºÇÉÀ̿Ͻð£
  • survival time
    »ýÁ¸±â°£
  • synaptic time
    ½Ã³À½ºÅë°ú½Ã°£, ¿¬Á¢Åë°ú½Ã°£
  • sedimentation time
    ħ°­½Ã°£
  • sinoatrial conduction time
    ±¼½É¹æÀüµµ½Ã°£, µ¿½É¹æÀüµµ½Ã°£
  • sinus node recovery time
    ±¼°áÀýȸº¹½Ã°£, µ¿°áÀýȸº¹½Ã°£
  • tear film breakup time
    ´«¹°¸·ÆÄ±«½Ã°£
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • time interval
    ½Ã°£°£°Ý
  • latent time
    Àẹ½Ã°£
  • lead time
    Á¶±â¹ß°ß±â°£
  • maximum phonation time
    ÃÖÀå¹ß¼ºÁö¼Ó½Ã°£
  • mean survival time
    Æò±Õ»ýÁ¸½Ã°£
  • mean tidal time
    Æò±Õ¼øÈ¯½Ã°£
  • time dependent relative risk model
    ½Ã°£ÀÇÁ¸»ó´ëÀ§Çè¸ðµ¨
  • partial thromboplastin time
    ºÎºÐÆ®·Òº¸ÇÃ¶ó½ºÆ¾½Ã°£
  • peak concentration time
    ÃÖ°í³óµµ½Ã°£
  • perception time
    Áö°¢½Ã°£, ÀνĽð£
  • person-time incidence rate
    »ç¶÷±â°£¹ß»ý·ü
  • phonation time
    ¹ß¼ºÁö¼Ó½Ã°£
  • polymerizing time
    ±»´Â½Ã°£, ÁßÇսð£
  • potential doubling time
    ÀáÀç¹è°¡½Ã°£
  • prothrombin time
    ÇÁ·ÎÆ®·Òºó½Ã°£
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • rotational energy level
    ȸÀü¿¡³ÊÁö¼öÁØ.
  • specific energy of sense
    Ư¼ö°¨°¢¿¡³ÊÁö.
  • specific nerve energy
    Ư¼ö½Å°æ(÷åâ¨ãêÌè) ¿¡³ÊÁö.
  • surface energy
    Ç¥¸é¿¡³ÊÁö.
  • thermal energy
    ¿­¿¡³ÊÁö
  • threshold energy
    ¿ªÄ¡¿¡³ÊÁö
  • threshold energy
    ¹®Åο¡³ÊÁö, ¿ªÄ¡(Ú¿ö·)¿¡³ÊÁö.
  • total potential energy
    ÃÑ(õÅ)À§Ä¡¿¡³ÊÁö.
  • total potential energy difference
    ÃÑÀ§Ä¡¿¡³ÊÁöÂ÷.
  • transformation of energy
    ¿¡³ÊÁöº¯È¯ (¡­Ü¨üµ).
  • vibrational energy
    Áøµ¿¿¡³ÊÁö<¿¡³×¸£±â>.
  • vital energy
    »ý¸í·Â(ßæÙ¤æ³).
  • acquisition time
    ȹµæ ½Ã°£
  • activated clotting time
    Ȱ¼ºÈ­ÀÀ°í½Ã°£
  • activated coagulation time(ACT)
    Ȱ¼º Ç÷¾× ÀÀ°í½Ã°£
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
RCM radial contour model; radiographic contrast medium; red cell mass; reinforced clostridial medium; re...
SIR single isomorphous replacement; specific immune release; standardized incidence ratio; syndrome of i...
TARA total articular replacement arthroplasty; tumor-associated rejection antigen
THP Tamm-Horstall protein; tetrahydropapaveroline; tissue hydrostatic pressure; total hip replacement; t...
THR targeted heart rate; threonine; thyroid hormone receptor; total hip replacement; transhepatic resist...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
DOE Department of Energy
DE Digestible energy
DEXA Dual Energy X Ray Absorptiometry
DXA Dual Energy X-ray Absorptiometry
EELS Electron Energy Loss Spectroscopy
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
real-time ultrasonography Rapid serial ultrasound images produced using a phased array or scanning transducer; produces a video display of organ motion, such as heart valve or foetal motion.
(05 Mar 2000)
recognition time The interval between the application of a stimulus and the recognition of its nature.
(05 Mar 2000)
partial thromboplastin time Test of the intrinsic (factors viii, ix, xi, and xii) and common (fibrinogen, prothrombin, factors v and x) pathways of coagulation in which a mixture of plasma and phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides) is recalcified and the time required for the appearance of fibrin strands measured. Activation may be provided by contact with the glass tube or exposure to activators (e.g., ellagic acid, particulate silicates such as diatomaceous earth or kaolin) before addition of the calcium chloride. It is used as a screening test and to monitor heparin therapy.
(12 Dec 1998)
relaxation time Time taken for a system to return to the resting or ground state or a new equilibrium state following perturbation. Often used in context of receptor systems that have a refractory period after responding and then relax to a competent state. Can be used more precisely to mean the time for a system to change from its original equilibrium value to 1/e of this original value.
(18 Nov 1997)
median time to elimination <pharmacology> The time it takes one half of a drug to be eliminated from the body.
(09 Oct 1997)
repetition time In magnetic resonance imaging, the time between repetitions of the pulse sequence.
(05 Mar 2000)
rise time The time required for a pulse or echo to rise from 10% to 90% of its peak amplitude.
(05 Mar 2000)
P-H conduction time See: atrioventricular conduction.
(05 Mar 2000)
running time The time during which an activity (e.g., chromatography development) occurs.
(05 Mar 2000)
Russell's viper venom clotting time A clotting time determination performed on citrated platelet-poor plasma using Russell's viper venom as an activating agent. This allows activation of factor X directly without the need for other coagulation factors and is used to confirm factor X defects.
See: Stypven time test.
(05 Mar 2000)
circulation time The time taken for the blood to pass through a given circuit of the vascular system, e.g., the pulmonary or systemic circulation, from one arm to another, from arm to tongue, or from arm to lung; it is measured by the injection into an arm vein of a substance, such as sodium dehydrocholate, ether, fluorescein, histamine, or a radium salt, which can be detected when it arrives at another point in the vascular system.
(05 Mar 2000)
clot retraction time The time required for a blood clot to separate from the tube wall and express serum, usually completed in 18 to 24 hours, but retarded or absent in persons with thrombocytopenic purpura.
(05 Mar 2000)
clotting time The time required for blood to coagulate; prolonged in haemophilia and in the presence of obstructive jaundice, some anaemias and leukaemias, and some of the infectious diseases.
Synonym: clotting time.
(05 Mar 2000)
coagulation time The time required for blood to coagulate; prolonged in haemophilia and in the presence of obstructive jaundice, some anaemias and leukaemias, and some of the infectious diseases.
Synonym: clotting time.
(05 Mar 2000)
collision time <radiobiology> Typical time which passes between two consecutive collision events for a given particle. Inverse of the collision frequency, equal to the mean free path divided by the particle's velocity. In plasmas, the (Coulomb) collision time decreases with increasing density, and increases with increasing temperature.
(09 Oct 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • green time
    ¤¼;û½ÅÈ£ ½Ã°£´ë(ÀÏ·ÃÀÇ ½ÅÈ£°¡ ¸ðµÎ û»öÀÌ µÇ´Â ½Ã°£)
  • half time
    ¹ÝÀÏ ±Ù¹«;¹ÝÀϱÞ;(½ºÆ÷Ã÷)ÇÏÇÁ ŸÀÓ;Áß°£ ÈÞ½Ä
  • half time
    ¹ÝÀÏ ³ëµ¿;¹ÝÀϱÞ;Áß°£ ÈÞ½Ä
  • high time
    ÁÁÀº ¶§(½Ã±â);È£±â;Èï°Ü¿ï(À¯ÄèÇÑ)¶§
  • hold time
    (·ÎÄÏ,¹Ì»çÀÏ ¹ß»ç½ÃÀÇ ÃÊÀбâ,ÀÛ¾÷ µîÀÇ)ÀϽÃÀû Áß´Ü(´ë±â)
  • lap time
    ÇÑ ¹ÙÄû µµ´Â ½Ã°£;ÀÏÁֽð£
  • lead time
    ±âȹ¿¡¼­ »ý»ê±îÁöÀÇ ½Ã°£;¹ßÁÖ¿¡¼­ ¹è´Þ±îÁöÀÇ ½Ã°£;¹ßÁÖ¿¡¼­ ¹è´Þ±îÁöÀÇ ½Ã°£
  • local time
    Áö¹æ½Ã;ÇöÁö ½Ã°£
  • machine time
    (ÄÄÇ»ÅÍ µîÀÇ) ÃÑ ÀÛµ¿½Ã(°£);ÀÛµ¿ ¿¬½Ã°£
  • mean solar time
    Æò±Õ žç½Ã;Æò±Õ½Ã
  • monkey time
    ¼­¸Ó ŸÀÓ
  • mountain time
    »êÁö Ç¥ÁؽÃ
  • needle time
    (¿µ)(¹æ¼Û)·¹ÄÚµå À½¾Ç½Ã°£
  • oneline real time system
    Á÷°á ½Ç½Ã°£ ó¸® ¹æ½Ä
  • part time
    Á¤»ó(±Ù¹«)½Ã°£ÀÇ ÀϺÎ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
ÅëÇÕ°Ë»ö ¿Ï·á